Clinicopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models

  • Authors:
    • Kyong-Hwa Jun
    • Jung Eun Lee
    • Se Hoon Kim
    • Ji-Han Jung
    • Hyun‑Joo Choi
    • Young Il Kim
    • Hyung-Min Chin
    • Seung-Ho Yang
  • View Affiliations

  • Published online on: August 10, 2015     https://doi.org/10.3892/or.2015.4191
  • Pages: 2047-2053
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gastric cancer is the second most common cause of cancer-related death worldwide. Although brain metastasis is a rare complication of gastric cancer, no standard therapy for gastric cancer brain metastasis has been established. We attempted to identify biological markers that predict brain metastasis, and investigated how to modulate such markers. A case-control study of patients newly diagnosed with gastric cancer who had developed brain metastasis during follow-up, was conducted. These patients were compared with patients who had advanced gastric cancer but no evidence of brain metastasis. Immunohistochemistry was used to analyze the expression of E-cadherin, N-cadherin, MSS1, claudin-3, claudin-4, Glut1, clusterin, ITGB4, vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR) and p53. The expression of VEGF tended to be higher in the case group (33.3 vs. 0%, p=0.055). Median survival was significantly correlated with vascular invasion (12 vs. 33 months, p=0.008) and N-cadherin expression (36 vs. 12 months, p=0.027). We also investigated the effects of metformin in tumor-bearing mouse models. VEGF expression was decreased and E-cadherin increased in the metformin‑treated group when compared with the control group. The expression of the mesenchymal marker MMP9 was decreased in the metformin-treated group. Brain metastasis of advanced gastric cancer was associated with the expression of VEGF. Metformin treatment may be useful for modulating the metastatic capacity by reducing VEGF expression and blocking epithelial-to-mesenchymal transition.
View Figures
View References

Related Articles

Journal Cover

October-2015
Volume 34 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Jun K, Lee JE, Kim SH, Jung J, Choi HJ, Kim YI, Chin H and Yang S: Clinicopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models. Oncol Rep 34: 2047-2053, 2015
APA
Jun, K., Lee, J.E., Kim, S.H., Jung, J., Choi, H., Kim, Y.I. ... Yang, S. (2015). Clinicopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models. Oncology Reports, 34, 2047-2053. https://doi.org/10.3892/or.2015.4191
MLA
Jun, K., Lee, J. E., Kim, S. H., Jung, J., Choi, H., Kim, Y. I., Chin, H., Yang, S."Clinicopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models". Oncology Reports 34.4 (2015): 2047-2053.
Chicago
Jun, K., Lee, J. E., Kim, S. H., Jung, J., Choi, H., Kim, Y. I., Chin, H., Yang, S."Clinicopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models". Oncology Reports 34, no. 4 (2015): 2047-2053. https://doi.org/10.3892/or.2015.4191